Gedeon Richter acquired BCI Pharma, a biotech focused on kinase inhibitors for neuropathic pain. The transaction marks a Fund I exit.
Gedeon Richter acquired BCI Pharma, a biotech focused on kinase inhibitors for neuropathic pain. The transaction marks a Fund I exit.